MAA Laboratories, Inc. is a specialty pharmaceutical company that reformulates existing anti-cancer drugs by utilizing a proprietary technology to produce products with competitive advantages by improving one or more of the following aspects: therapeutic efficiency, targeted drug delivery, and/or mitigation of undesirable effects. Long term, MAA will integrate reformulation technology with continuous process technology to reduce average drug product production time by 50%.
As part of the reformulation process, MAA Laboratories will conduct pre-clinical studies for safety and efficacy. Phase I clinical studies in healthy volunteers will be outsourced to a contract clinical research organization (CRO). After successful conclusion of a Phase I clinical trial, the highly improved products will be licensed to strategic partners for further development under standard terms for the industry.